EZH2 and hepatocellular carcinoma: Recently, it has also been found that acquired resistance toward Infigratinib in hepatocellular carcinoma correlates with higher phosphorylation levels of ERBB2/3 and increased EZH2 expression (Prawira et al, 2021).